For patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer who had failed to meet with anthracycline or taxane, the application of HER2-targeted antibody-drug conjugates as second-line therapy could improve patients' outcomes, but it is unclear whether carboplatin-based first-line therapy will benefit these patients. Here, ERBB2 is linked to breast cancer.